Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health's Board Approves $30M Share Repurchase Program

NEW YORK (GenomeWeb News) – Genomic Health's board has approved a $30 million share repurchase program, the Redwood City, Calif.-based firm said in a document filed with the US Securities and Exchange Commission today.

Repurchases made under the program will be funded using the firm's working capital. As of Sept. 30, Genomic Health had cash and cash equivalents, and investments and marketable securities totaling $127 million. It had about 30.8 million shares of common stock outstanding as of Nov. 30.

Repurchases made under the program may be made pursuant to a "collared" accelerated share repurchase agreement with JP Morgan Securities, which becomes effective Dec. 12, Genomic Health said.

The number of shares to be repurchased under that agreement will be determined by the "average daily volume weighted average prices of shares traded during the term of the agreement," said Genomic Health. The minimum and maximum number of shares will depend on the results of an initial hedge to be established by the investment bank, the firm added.

The repurchases made as part of the $30 million program may also be pursuant to a pre-arranged Rule10b5-1 share repurchase plan, an SEC regulation covering certain insider trading rules.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.